PaxVax, in collaboration with the U.S. Army, initiates clinical trials of a modernized Adenovirus vaccine

Monday, May 8, 2017

PaxVax, a leading independent specialty vaccine company, announced today the initiation of a new clinical trial program, in collaboration with the U.S. Army Medical Material Development Activity and the Walter Reed Army Institute of Research to protect U.S. military personnel. This is the first initiative to modernize the Adenovirus Serotypes 4 and 7 (Ad 4/7) vaccine in more than 30 years. PaxVax is developing an updated and improved version of the vaccine. The vaccine, known as the Modernized Production Adenovirus Vaccine (MPAV) Prototype A, will ultimately be administered to U.S. service members during basic training. [Read More]

FDA approves Vaxchora, PaxVax’s single-dose oral cholera vaccine

Friday, June 17, 2016

PaxVax has received marketing approval from the FDA for Vaxchora, a single-dose oral, live attenuated cholera vaccine indicated for use in adults 18 to 64 years of age. Vaxchora is the only vaccine available in the U.S. for protection against cholera and the only single-dose vaccine for cholera currently licensed anywhere in the world.

[Read More]